Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Bioretec

0.05 EUR

-3.85 %

1,732 following
Corporate customer

BRETEC

First North Finland

Medical Equipment & Services

Health Care

-3.85 %
+99.27 %
-9.33 %
-9.33 %
-68.00 %
-73.95 %
-80.68 %
-
-80.69 %

Bioretec operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other materials for bone and soft tissue injuries. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in the Nordic region.

Read more
Market cap
75.43M EUR
Turnover
16.37K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
30.03.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 30.03.2026

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
8.5.
2026

General meeting '26

15.5.
2026

Business review Q1'26

13.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Some buyer unfamiliar with the matter is on the buy side of the stock market, offering an opportunity to sell shares to them at an inflated price. Yes, the price will drop, at the latest when the share issue project has been completed and the harsh reality dawns on the majority of...
11 hours ago
by Nordman09
7
Here are Antti’s thoughts on, among other things, the rights issue, in the form of a company report. Bioretec announced the terms of its rights issue on Friday. The company aims to raise a maximum of 14.8 MEUR. The minimum target of 5 MEUR for the issue is guaranteed by the main ...
3/30/2026, 5:21 AM
by Sijoittaja-alokas
7
Inside Information: Bioretec Oy’s Board of Directors Decided on a Rights Offering of a Maximum of Approximately EUR 14.8 Million and Publishes the Terms of the Rights Offering Inderes Sisäpiiritieto: Bioretec Oy:n hallitus päätti enintään noin 14,8 miljoonan... Bioretec Oy Sisäpiiritieto...
3/27/2026, 12:50 PM
by Index
4
I have exactly the same thoughts. Absolutely incomprehensible bungling that has wiped out 92% of the market value in a year. I also thought a share issue was coming and that I would probably participate. However, those share issue terms were the final red flag (I know, if you subscribe...
3/13/2026, 11:17 AM
by Kim Blomqvist
3
I’m a bit puzzled by Bioretec’s share price… Before the warrants were spun off on Fri 27.3., the share price was about 14c and the company’s market value was 4.31m. Today, according to Nordnet, the company has 1,508,616,508 shares, which, at a share price of 5 cents, results in a...
yesterday
by Timo Heikkerö
2
A couple of months ago Inderes Tuukka Paavola on nimitetty Bioretecin talousjohtajaksi - Inderes Bioretec Oy Yhtiötiedote 15.1.2026 kello 17:30 EETBiohajoavien ortopedisten implanttien edelläkävijä Bioretec Oy, on nimittänyt Tuukka Paavolan (DI, CFA) talousjohtajaksi 20. tammikuuta...
3/13/2026, 2:28 PM
by Vino Pino
2
The market isn’t always efficient. I don’t think it’s anything more than inertia.
yesterday
by TZ
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.